Company profile

Nanjing Chia-tai Tianqing Pharmaceutical

Privately held: no public share price (A core operating subsidiary of HKEX-listed Sino Biopharmaceutical; not separately listed. Parent: Sino Biopharmaceutical Limited (HKEX 1177). [resolved 2026-08-05 by resolve-null-is-public; source: https://govt.chinadaily.com.cn/s/201902/01/WS5c540a1a498e27e338038005/nanjing-chia-tai-tianqing-pharmaceutical-co-ltd.html]) · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
NTQ1062
Phase 3
AKT (inhibitor)Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
NTQ2494
Phase 1
AXL
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.